title: Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not).
authors.forename: Salvatore Maria
authors.initials: SM
authors.lastname: Corsello
authors.forename: Roberto
authors.initials: R
authors.lastname: Salvatori
authors.forename: Agnese
authors.initials: A
authors.lastname: Barnabei
authors.forename: Liana
authors.initials: L
authors.lastname: De Vecchis
authors.forename: Paolo
authors.initials: P
authors.lastname: Marchetti
authors.forename: Francesco
authors.initials: F
authors.lastname: Torino
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D004700:Endocrine System Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D007018:Hypopituitarism / Q000139:chemically induced; D000074324:Ipilimumab; D008775:Methylprednisolone / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000139:chemically induced / Q000188:drug therapy
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D011241:Prednisone; D008775:Methylprednisolone